BridgeMD
Compares treatment options for HELICOBACTER PYLORI INFECTIONS
Official title Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial
ClinicalTrials.gov ID: NCT07179159
What this study is testing
What is 14-day vonoprazan-amoxicillin dual therapy?
14-day vonoprazan-amoxicillin dual therapy is an investigational medicine, being studied as a potential treatment for helicobacter pylori infections.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a multicentre, non-inferiority randomized controlled trial to compare the efficacy and safety of 14-day vonoprazan-based dual therapy with versus quadruple therapy for the eradication of Helicobacter pylori. The primary outcome is eradication rate, and the secondary outcome includes the incidence of adverse events and compliance.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Aged 18-70 years, male or female
- Patients with H. pylori infection (positive 13C-urea breath test, together with at least one positive result from the following three tests: (a)...
- No prior Helicobacter pylori eradication therapy
You likely can't join if
- Severe underlying conditions, such as hepatic insufficiency, renal insufficiency, malignant tumours
- Active gastrointestinal bleeding
- History of upper gastrointestinal surgery
- History of drug hypersensitivity
- Use of bismuth compounds or antibiotics within the past 4 weeks, or acid-suppressing agents within the past 2 weeks
- Pregnant or lactating women
See the full eligibility criteria
- Aged 18-70 years, male or female
- Patients with H. pylori infection (positive 13C-urea breath test, together with at least one positive result from the following three tests: (a) stool H. pylori antigen test; (b) rapid urease test; (c) histopathological...
- No prior Helicobacter pylori eradication therapy
- Severe underlying conditions, such as hepatic insufficiency, renal insufficiency, malignant tumours
- Active gastrointestinal bleeding
- History of upper gastrointestinal surgery
- History of drug hypersensitivity
- Use of bismuth compounds or antibiotics within the past 4 weeks, or acid-suppressing agents within the past 2 weeks
- Pregnant or lactating women
- Presence of other risk-increasing behaviours such as alcohol abuse or illicit drug use
- Individuals unable or unwilling to provide informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Jinan, Shandong, China
- Jinan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jinan, Shandong, China; Jinan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.